Because both cancer cells and immunoinhibitory immune cells can represent a source of supply of IL-8 in the TME, a remaining issue would be to determine which of these factors affected by lenvatinib contributes more to the decrease in IL-8. The gene discussed is CXCL8; the disease is cancer.